NCT02353728View on ClinicalTrials.gov

Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy

PHASE2CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

February 28, 2021

Study Completion Date

February 28, 2021

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG

Nilotinib

Trial Locations (1)

10065

Weill Cornell Medical College, New York

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER